Seedlabs

CDH2 Prodomain Cleavage Assay: VUS Resolution for Neurodevelopmental Labs

A lab service that tests specific genetic variants to see if they break a protein needed for brain development.

A lab service that runs a furin-cleavage peptide assay on CDH2 variants of uncertain significance from neurodevelopmental exomes, telling diagnostic labs whether a variant actually breaks N-cadherin maturation.

MedicineAttention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderDiagnostic laboratory variant interpretation (VUS resolution services)

Concept

A variant-interpretation service for diagnostic laboratories: when a neurodevelopmental exome or panel returns a CDH2 variant of uncertain significance (VUS) in a child with ADHD or related symptoms, the lab reflexes the variant to this service, which runs the paper's in vitro furin-cleavage peptide assay — plus a neuronal N-cadherin maturation readout — and returns a structured functional classification (impaired / partial / normal prodomain processing) that the lab can fold into ACMG-style variant reclassification.

Why now

Paper [0] shows the path from variant to mechanism is measurable with a simple, scalable biochemical assay: the p.H150Y mutation significantly decreases the proteolytic cleavage efficacy of the N-cadherin prodomain by furin protease in an in vitro peptide cleavage assay, and that maturation defect tracks the full downstream phenotype — smaller presynaptic vesicle clusters, a smaller readily releasable pool, reduced mEPSC frequency, and reduced tyrosine hydroxylase and dopamine. With CDH2 now on the map as a human ADHD gene, labs sequencing neurodevelopmental genes will increasingly encounter CDH2 VUS they currently have no way to resolve; a peptide-synthesis-plus-cleavage-readout assay is cheap and fast relative to animal or iPSC-neuron work, and fits the existing VUS-referral workflows that commercial labs already use for other genes.

Written by GLM · 13 Oct 2026

AI assessment

Backed by 1 paper92

A highly focused, evidence-backed diagnostic service that converts a specific biochemical finding into a high-value clinical utility for VUS resolution.

Evidence strength
5/5
The idea directly maps to the paper's specific finding that the p.H150Y mutation impairs furin-mediated prodomain cleavage, which the authors explicitly link to the ADHD phenotype.
Market pull
4/5
Diagnostic labs like GeneDx and LabCorp have a strong incentive to resolve VUS to provide definitive diagnoses, and the ADHD market is substantial.
Novelty & moat
4/5
Unlike the listed ideas which are mostly software-based scoring or panels, this is a physical functional assay service for a specific protein mechanism.
Feasibility
5/5
The assay is described as a simple in vitro peptide cleavage test, which is significantly easier and faster to implement than cell-based or animal models.
Wedge clarity
5/5
The wedge is extremely sharp: a single-protein, single-mechanism assay for a specific set of clinical labs.
Simplicity / focus
5/5
The product is a single, well-defined lab service rather than an over-scoped platform.

Scored by Gemma 4 · 13 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • GeneDxcompany

    Returns thousands of neurodevelopmental exomes; a reflex cleavage assay turns CDH2 VUS into actionable classifications and reduces uninformative reports.

  • LabCorpcompany

    Absorbed Invitae's exome/genome business; could reflex CDH2 VUS to the assay as part of its variant-reclassification workflow.

  • Ambry Geneticscompany

    Quest-owned lab with neurodevelopmental panel offerings; functional classification data would strengthen its CDH2 curation and reporting.

  • Baylor Geneticscompany

    Exome-sequencing lab that could offer the assay as a reflex option for ADHD and neurodevelopmental findings.

Research it builds on

  1. CDH2 mutation affecting N-cadherin function causes attention-deficit hyperactivity disorder in humans and mice
    Daniel S. Halperin, Alexandra Stavsky, Rotem Kadir et al. · 2021 · 42 citations
    All ideas from this paper →
Leave feedback
feasibility